{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:03:49Z","timestamp":1792843429461,"version":"4.5.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cmi.2023.04.015","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T07:46:47Z","timestamp":1681976807000},"page":"1015-1023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["How to diagnose and treat a patient without human immunodeficiency virus infection having Pneumocystis jirovecii pneumonia?"],"prefix":"10.1016","volume":"29","author":[{"given":"L.","family":"H\u00e4nsel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.04.015_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1550-7408.2005.00072.x","article-title":"Pneumocystis and Trypanosoma cruzi: nomenclature and typifications","volume":"53","author":"Redhead","year":"2006","journal-title":"J\u00a0Eukaryot Microbiol"},{"key":"10.1016\/j.cmi.2023.04.015_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02906-22","article-title":"Anidulafungin treatment blocks the sexual cycle of Pneumocystis murina and prevents growth and survival without rescue by an alternative mode of replication","volume":"10","author":"Cushion","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2023.04.015_bib3","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1093\/cid\/ciaa1805","article-title":"Pneumocystis jirovecii disease: basis for the revised EORTC\/MSGERC invasive fungal disease definitions in individuals without human immunodeficiency virus","volume":"72","author":"Lagrou","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jiac.2017.07.003","article-title":"A\u00a0study on the colonization of Pneumocystis jirovecii among outpatients during cancer chemotherapy and among healthy smokers","volume":"23","author":"Takemoto","year":"2017","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2023.04.015_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.pt.2021.07.010","article-title":"Pneumocystis pneumonia in the COVID-19 pandemic era: similarities and challenges","volume":"37","author":"Szyd\u0142owicz","year":"2021","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.cmi.2023.04.015_bib6","article-title":"Pneumocystis primary infection in non-immunosuppressed infants in Lima, Peru","volume":"32","author":"Ochoa","year":"2022","journal-title":"J\u00a0Mycol Med"},{"key":"10.1016\/j.cmi.2023.04.015_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1051\/parasite\/2011182121","article-title":"Pneumocystis jirovecii colonization in chronic pulmonary disease","volume":"18","author":"Guti\u00e9rrez","year":"2011","journal-title":"Parasite"},{"key":"10.1016\/j.cmi.2023.04.015_bib8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fcimb.2020.00224","article-title":"Epidemiology of Pneumocystis jirovecii pneumonia and (non-)use of prophylaxis","volume":"10","author":"Dunbar","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2023.04.015_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2362.2010.02415.x","article-title":"Pneumocystis jirovecii colonization in patients treated with infliximab","volume":"41","author":"Wissmann","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cmi.2023.04.015_bib10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/mmy\/myaa107","article-title":"The shift from pulmonary colonization to pneumocystis pneumonia","volume":"59","author":"Le Gal","year":"2021","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2023.04.015_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.30699\/ijp.13.2.136","article-title":"Colonization of Pneumocystis jirovecii in patients who received and not received corticosteroids admitted to the intensive care unit: airborne transmission approach","volume":"13","author":"Mohammadi-Ghalehbin","year":"2018","journal-title":"Iran J Pathol"},{"key":"10.1016\/j.cmi.2023.04.015_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1086\/653933","article-title":"Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with pneumocystis pneumonia","volume":"51","author":"Choukri","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib13","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1093\/cid\/cir996","article-title":"A\u00a0cluster of pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii","volume":"54","author":"Le Gal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/TP.0b013e3182a1618c","article-title":"Outbreak of pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of Pneumocystis jirovecii","volume":"96","author":"Rostved","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2023.04.015_bib15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/513198","article-title":"An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source?","volume":"44","author":"de Boer","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fpubh.2019.00275","article-title":"Changing trends in the epidemiology and risk factors of pneumocystis pneumonia in Spain","volume":"7","author":"Pereira-D\u00edaz","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.cmi.2023.04.015_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7883\/yoken.JJID.2018.400","article-title":"Epidemiologic trends and clinical features of Pneumocystis jirovecii pneumonia in non-HIV patients in a tertiary-care hospital in Korea over a 15-year-period","volume":"72","author":"Lee","year":"2019","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib18","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1099\/jmm.0.000617","article-title":"Changing epidemiology of pneumocystis pneumonia, Northern Ireland, UK and implications for prevention","volume":"66","author":"Patterson","year":"2017","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.cmi.2023.04.015_bib19","article-title":"Clinical characteristics and risk factors of in-hospital mortality in patients coinfected with Pneumocystis jirovecii and Aspergillus","volume":"33","author":"Zhong","year":"2023","journal-title":"J\u00a0Mycol Med"},{"key":"10.1016\/j.cmi.2023.04.015_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01138-21","article-title":"COVID-19-associated pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the intensive care unit: a retrospective multicenter observational cohort during the first French pandemic wave","volume":"9","author":"Bretagne","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2023.04.015_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/00365548.2013.865142","article-title":"Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment","volume":"46","author":"Roblot","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4065\/71.1.5","article-title":"Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy","volume":"71","author":"Yale","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cmi.2023.04.015_bib23","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s10067-021-05660-4","article-title":"Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study","volume":"40","author":"Hsu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cmi.2023.04.015_bib24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.12-0477","article-title":"Pneumocystis pneumonia in patients treated with rituximab","volume":"144","author":"Martin-Garrido","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2023.04.015_bib25","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.24499","article-title":"Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy","volume":"91","author":"Barreto","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2023.04.015_bib26","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2352-3026(19)30104-8","article-title":"Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2023.04.015_bib27","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2023.04.015_bib28","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","article-title":"Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup Study Cancer and Leukemia Group B 9011","volume":"19","author":"Morrison","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2023.04.015_bib29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clml.2011.07.006","article-title":"Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders","volume":"12","author":"Obeid","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.cmi.2023.04.015_bib30","article-title":"Outcomes and risk factors for mortality in pneumocystis pneumonia patients with rheumatoid arthritis: a multicenter retrospective cohort study","author":"Mori","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cmi.2023.04.015_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/07357900701206380","article-title":"Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide","volume":"25","author":"Schwarzberg","year":"2007","journal-title":"Cancer Invest"},{"key":"10.1016\/j.cmi.2023.04.015_bib32","doi-asserted-by":"crossref","first-page":"e1456","DOI":"10.1093\/cid\/ciaa1611","article-title":"Identification of predictive markers and outcomes of late-onset Pneumocystis jirovecii pneumonia in kidney transplant recipients","volume":"73","author":"Kaminski","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib33","doi-asserted-by":"crossref","first-page":"598","DOI":"10.12659\/AOT.908471","article-title":"Early sirolimus-based immunosuppression is safe for lung transplantation patients: retrospective, single arm, exploratory study","volume":"23","author":"Wojarski","year":"2018","journal-title":"Ann Transplant"},{"key":"10.1016\/j.cmi.2023.04.015_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106019","article-title":"Pneumocystis pneumonia after lung transplantation: a retrospective multicenter study","volume":"169","author":"Delbove","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.cmi.2023.04.015_bib35","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00228-019-02730-0","article-title":"m-TOR inhibitors and risk of pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysis","volume":"75","author":"Ghadimi","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2023.04.015_bib36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1159\/000508632","article-title":"Opportunistic and serious infections in patients with neuroendocrine tumors treated with everolimus: a multicenter study of real-world patients","volume":"111","author":"Mauro","year":"2021","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.cmi.2023.04.015_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12709","article-title":"High-dose calcineurin inhibitor-free everolimus as a maintenance regimen for heart transplantation may be a risk factor for pneumocystis pneumonia","volume":"19","author":"Hu","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib38","article-title":"Pneumocystis pneumonia in patients with autoimmune diseases: a retrospective study focused on clinical characteristics and prognostic factors related to death","volume":"10","author":"Chen","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cmi.2023.04.015_bib39","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.transproceed.2017.12.059","article-title":"Immunosuppressive treatment and its effect on the occurrence of Pneumocystis jiroveci, Mycoplasma pneumoniae, Chlamydophila pnemoniae, and Legionella pneumophila infections\/colonizations among lung transplant recipients","volume":"50","author":"Wojarski","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cmi.2023.04.015_bib40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamaoncol.2019.3994","article-title":"Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs medicare beneficiaries","volume":"6","author":"Bird","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cmi.2023.04.015_bib41","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.04.015_bib42","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1023\/B:DDAS.0000042246.58984.98","article-title":"Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn\u2019s disease","volume":"49","author":"Kaur","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cmi.2023.04.015_bib43","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cmi.2023.04.015_bib44","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.04.015_bib45","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.04.015_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13054-018-2221-8","article-title":"Clinical course, treatment and outcome of pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years","volume":"22","author":"Schmidt","year":"2018","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2023.04.015_bib47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.bmt.1704636","article-title":"Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea","volume":"34","author":"Yoo","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2023.04.015_bib48","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10096-006-0149-4","article-title":"Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients","volume":"25","author":"Torres","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcyt.2019.11.002","article-title":"High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era","volume":"22","author":"Evernden","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.cmi.2023.04.015_bib50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.mayocp.2020.07.029","article-title":"Host factors and outcomes in hospitalizations for Pneumocystis jirovecii pneumonia in the United States","volume":"96","author":"Kanj","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cmi.2023.04.015_bib51","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jiac.2020.07.006","article-title":"Recent epidemiology of pneumocystis pneumonia in Japan","volume":"26","author":"Shoji","year":"2020","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2023.04.015_bib52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1034\/j.1399-3062.2003.00018.x","article-title":"Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study","volume":"5","author":"Radisic","year":"2003","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12735","article-title":"Risk factors for pneumocystis pneumonia after the first 6 months following renal transplantation","volume":"19","author":"Faure","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib54","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00007890-198606000-00012","article-title":"Infections in heart-lung transplant recipients","volume":"41","author":"Dummer","year":"1986","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2023.04.015_bib55","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1164\/ajrccm\/137.6.1268","article-title":"Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation. Implications for lung defense and allograft survival","volume":"137","author":"Gryzan","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib56","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/339548","article-title":"Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome","volume":"34","author":"Sepkowitz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib57","first-page":"795","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2023.04.015_bib58","first-page":"1186","article-title":"Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus","volume":"23","author":"Kadoya","year":"1996","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2023.04.015_bib59","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00277-021-04452-9","volume":"100","author":"Classen","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2023.04.015_bib60","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199503163321101","article-title":"A\u00a0randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group","volume":"332","author":"Bozzette","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.04.015_bib61","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJM199104183241602","article-title":"A\u00a0controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia","volume":"324","author":"Hirschel","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.04.015_bib62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ki.2009.377","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary","volume":"77","author":"Kasiske","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2023.04.015_bib63","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12119","article-title":"Pneumocystis pneumonia in solid organ transplantation","volume":"13","author":"Martin","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2023.04.015_bib64","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12941-021-00483-2","article-title":"Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study","volume":"20","author":"Chan","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.cmi.2023.04.015_bib66","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1705149","article-title":"Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study","volume":"36","author":"De Castro","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2023.04.015_bib67","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.chest.2021.11.007","article-title":"Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab","volume":"161","author":"Park","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2023.04.015_bib68","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.transproceed.2021.03.026","article-title":"The changing landscape of Pneumocystis jiroveci infection in kidney transplant recipients: single-center experience of late-onset pneumocystis pneumonia","volume":"53","author":"Marinaki","year":"2021","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cmi.2023.04.015_bib69","doi-asserted-by":"crossref","DOI":"10.6002\/ect.2020.0080","article-title":"Pneumocystis jirovecii pneumonia in solid-organ transplant recipients: a national center experience","author":"Ozgen Alpaydin","year":"2020","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.cmi.2023.04.015_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13245","article-title":"Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: a case-control study","volume":"22","author":"Park","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib71","doi-asserted-by":"crossref","first-page":"625","DOI":"10.12659\/AOT.918195","article-title":"Impact of increased duration of trimethoprim-sulfamethoxazole prophylaxis for pneumocystis pneumonia after renal transplant","volume":"24","author":"Chapman","year":"2019","journal-title":"Ann Transplant"},{"key":"10.1016\/j.cmi.2023.04.015_bib72","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1164\/ajrccm\/140.5.1204","article-title":"Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS","volume":"140","author":"Limper","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib73","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/JCM.03494-14","article-title":"Cellular profiles of bronchoalveolar lavage fluid and their prognostic significance for non-HIV-infected patients with Pneumocystis jirovecii pneumonia","volume":"53","author":"Lee","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2023.04.015_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijid.2016.03.018","article-title":"Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients","volume":"46","author":"Bienvenu","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib75","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pulmoe.2019.04.003","article-title":"Pneumocystosis pneumonia: a comparison study between HIV and non-HIV immunocompromised patients","volume":"25","author":"Rego de Figueiredo","year":"2019","journal-title":"Pulmonology"},{"key":"10.1016\/j.cmi.2023.04.015_bib76","first-page":"28","article-title":"Clinical profile of Pneumocystis jirovecii infection - a comparative study","volume":"66","author":"Deodhar","year":"2018","journal-title":"J\u00a0Assoc Physicians India"},{"key":"10.1016\/j.cmi.2023.04.015_bib77","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/cc6806","article-title":"Critical care management and outcome of severe pneumocystis pneumonia in patients with and without HIV infection","volume":"12","author":"Monnet","year":"2008","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2023.04.015_bib78","doi-asserted-by":"crossref","first-page":"W555","DOI":"10.2214\/AJR.11.7329","article-title":"Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection","volume":"198","author":"Kanne","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.cmi.2023.04.015_bib79","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1469-0691.2010.03400.x","article-title":"Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients","volume":"17","author":"Alanio","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.04.015_bib80","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/mmy\/myaa024","article-title":"Diagnosing Pneumocystis jirovecii pneumonia: a review of current methods and novel approaches","volume":"58","author":"Bateman","year":"2020","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2023.04.015_bib81","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/aid.2015.0213","article-title":"Short communication: diagnosis of Pneumocystis jirovecii pneumonia by detection of DNA in blood and oropharyngeal wash, compared with sputum","volume":"32","author":"van Halsema","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.cmi.2023.04.015_bib82","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1128\/JCM.36.7.2068-2072.1998","article-title":"Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples","volume":"36","author":"Helweg-Larsen","year":"1998","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2023.04.015_bib83","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1086\/324520","article-title":"The use of oral washes to diagnose Pneumocystis carinii pneumonia: a blinded prospective study using a polymerase chain reaction-based detection system","volume":"184","author":"Fischer","year":"2001","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib84","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/mmy\/myu087","article-title":"Utility of adding Pneumocystis jirovecii DNA detection in nasopharyngeal aspirates in immunocompromised adult patients with febrile pneumonia","volume":"53","author":"Guigue","year":"2015","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2023.04.015_bib85","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01186-14","article-title":"Pneumocystis jirovecii can be productively cultured in differentiated CuFi-8 airway cells","volume":"5","author":"Schildgen","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2023.04.015_bib86","article-title":"Inability to culture","volume":"9","author":"Liu","year":"2018","journal-title":"Pneumocystis jirovecii"},{"key":"10.1016\/j.cmi.2023.04.015_bib87","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.04.015_bib88","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1378\/chest.08-1309","article-title":"Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates","volume":"135","author":"Azoulay","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2023.04.015_bib89","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/jac\/dkw156","article-title":"ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Alanio","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.04.015_bib90","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1183\/09031936.00095811","article-title":"Quantitative PCR to diagnose pneumocystis pneumonia in immunocompromised non-HIV patients","volume":"39","author":"M\u00fchlethaler","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2023.04.015_bib91","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1128\/JCM.02390-10","article-title":"Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay","volume":"49","author":"Hauser","year":"2011","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2023.04.015_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.729193","article-title":"Quantitative PCR to discriminate between pneumocystis pneumonia and colonization in HIV and non-HIV immunocompromised patients","volume":"12","author":"Sarasombath","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2023.04.015_bib93","article-title":"Effectiveness of a real-time PCR for diagnosis of pneumocystis pneumonia in immunocompromised patients - experience from a tertiary care center, India","volume":"32","author":"D","year":"2022","journal-title":"J\u00a0Mycol Med"},{"key":"10.1016\/j.cmi.2023.04.015_bib94","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.pathol.2021.03.006","article-title":"Quantitative Pneumocystis jirovecii real-time PCR to differentiate disease from colonisation","volume":"53","author":"Tan","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.cmi.2023.04.015_bib95","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/myc.12787","article-title":"Performance of serum (1,3)-\u03b2-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies","volume":"61","author":"Furfaro","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2023.04.015_bib96","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1093\/jac\/dkw299","article-title":"1,3-beta-d-Glucan contamination of common antimicrobials-authors\u2019 response","volume":"71","author":"Liss","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.04.015_bib97","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/myc.12432","article-title":"1,3-\u03b2-D-glucan concentrations in blood products predict false positive post-transfusion results","volume":"59","author":"Liss","year":"2016","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2023.04.015_bib98","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cmi.2020.05.024","article-title":"Diagnostic accuracy of serum (1-3)-beta-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis","volume":"26","author":"Del Corpo","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.04.015_bib99","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/cid\/ciy1072","article-title":"Clinical performance of (1,3) beta-D glucan for the diagnosis of pneumocystis pneumonia (PCP) in cancer patients tested with pcp polymerase chain reaction","volume":"69","author":"Morjaria","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib100","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/myc.12997","article-title":"Combination of beta-(1, 3)-D-glucan testing in serum and qPCR in nasopharyngeal aspirate for facilitated diagnosis of Pneumocystis jirovecii pneumonia","volume":"62","author":"Desoubeaux","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2023.04.015_bib101","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cmi.2021.08.017","article-title":"Non-invasive diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis","volume":"28","author":"Sen\u00e9cal","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.04.015_bib102","article-title":"Metagenomic next-generation sequencing is highly efficient in diagnosing Pneumocystis jirovecii pneumonia in the immunocompromised patients","volume":"13","author":"Wang","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2023.04.015_bib103","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00101-22","article-title":"Accuracy of Pneumocystis jirovecii plasma cell-free DNA PCR for noninvasive diagnosis of pneumocystis pneumonia","volume":"60","author":"Moreno","year":"2022","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2023.04.015_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/srep36287","article-title":"Serological diagnosis of pneumocystosis: production of a synthetic recombinant antigen for immunodetection of Pneumocystis jirovecii","volume":"6","author":"Tom\u00e1s","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2023.04.015_bib105","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3201\/eid2009.131668","article-title":"Pneumocystis jirovecii pneumonia in patients with or without AIDS, France","volume":"20","author":"Roux","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib106","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1128\/AAC.15.3.447","article-title":"Clinical pharmacology of intravenously administered trimethoprim-sulfamethoxazole","volume":"15","author":"Grose","year":"1979","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.04.015_bib107","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkw158","article-title":"ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients","volume":"71","author":"Maschmeyer","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.04.015_bib108","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13587","article-title":"Pneumocystis jiroveci in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Fishman","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cmi.2023.04.015_bib109","first-page":"856","article-title":"Update on dihydropteroate synthase (DHPS) mutations in Pneumocystis jirovecii","volume":"7","author":"de la Horra","year":"2021","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.cmi.2023.04.015_bib110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1471-2334-11-76","article-title":"Clinical characteristics of pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes","volume":"11","author":"Matsumura","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib111","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1469-0691.2010.03452.x","article-title":"Beta-d-glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia","volume":"17","author":"Held","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.04.015_bib112","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.ejrad.2011.02.052","article-title":"HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients","volume":"81","author":"Vogel","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cmi.2023.04.015_bib113","doi-asserted-by":"crossref","first-page":"ofaa112","DOI":"10.1093\/ofid\/ofaa112","article-title":"Low-dose TMP-SMX in the treatment of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis","volume":"7","author":"Butler-Laporte","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib114","doi-asserted-by":"crossref","first-page":"e1252","DOI":"10.1093\/cid\/ciac386","article-title":"Treatment with reduced-dose trimethoprim-sulfamethoxazole is effective in mild to moderate Pneumocystis jirovecii pneumonia in patients with hematologic malignancies","volume":"76","author":"Hammarstr\u00f6m","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.015_bib115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008524","article-title":"Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection","volume":"5","author":"Cushion","year":"2010","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cmi.2023.04.015_bib116","first-page":"1594","article-title":"Efficacy of caspofungin combined with trimethoprim\/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.cmi.2023.04.015_bib117","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2023.04.015_bib118","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3892\/etm.2015.2929","article-title":"Adjunctive corticosteroids for the treatment of Pneumocystis jiroveci pneumonia in patients with HIV: a meta-analysis","volume":"11","author":"Wang","year":"2016","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.cmi.2023.04.015_bib119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250611","article-title":"Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology patients with Pneumocystis jirovecii pneumonia: a propensity score analysis","volume":"16","author":"Assal","year":"2021","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cmi.2023.04.015_bib120","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.chest.2018.04.026","article-title":"Early corticosteroids for pneumocystis pneumonia in adults without HIV are not associated with better outcome","volume":"154","author":"Wieruszewski","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2023.04.015_bib121","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01992-20","article-title":"Efficacy of rezafungin in prophylactic mouse models of invasive candidiasis, aspergillosis, and pneumocystis pneumonia","volume":"65","author":"Miesel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.04.015_bib122","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab545","article-title":"On the treatment of Pneumocystis jirovecii pneumonia: current practice based on outdated evidence","volume":"8","author":"McDonald","year":"2021","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23001866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23001866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:34:05Z","timestamp":1761118445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X23001866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":122,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1198743X23001866"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.04.015","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to diagnose and treat a patient without human immunodeficiency virus infection having Pneumocystis jirovecii pneumonia?","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}